Suppr超能文献

新冠病毒的一年:病毒发生了多大变化?

One Year of SARS-CoV-2: How Much Has the Virus Changed?

作者信息

Vilar Santiago, Isom Daniel G

机构信息

Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.

Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.

出版信息

Biology (Basel). 2021 Jan 26;10(2):91. doi: 10.3390/biology10020091.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide crisis with profound effects on both public health and the economy. In order to combat the COVID-19 pandemic, research groups have shared viral genome sequence data through the Global Initiative on Sharing All Influenza Data (GISAID). Over the past year, ≈290,000 full SARS-CoV-2 proteome sequences have been deposited in the GISAID. Here, we used these sequences to assess the rate of nonsynonymous mutants over the entire viral proteome. Our analysis shows that SARS-CoV-2 proteins are mutating at substantially different rates, with most of the viral proteins exhibiting little mutational variability. As anticipated, our calculations capture previously reported mutations that arose in the first months of the pandemic, such as D614G (Spike), P323L (NSP12), and R203K/G204R (Nucleocapsid), but they also identify more recent mutations, such as A222V and L18F (Spike) and A220V (Nucleocapsid), among others. Our comprehensive temporal and geographical analyses show two distinct periods with different proteome mutation rates: December 2019 to July 2020 and August to December 2020. Notably, some mutation rates differ by geography, primarily during the latter half of 2020 in Europe. Furthermore, our structure-based molecular analysis provides an exhaustive assessment of SARS-CoV-2 mutation rates in the context of the current set of 3D structures available for SARS-CoV-2 proteins. This emerging sequence-to-structure insight is beginning to illuminate the site-specific mutational (in)tolerance of SARS-CoV-2 proteins as the virus continues to spread around the globe.

摘要

严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发了一场全球危机,对公共卫生和经济都产生了深远影响。为了抗击新冠疫情,多个研究团队通过全球共享流感数据倡议组织(GISAID)分享了病毒基因组序列数据。在过去一年里,约29万条完整的SARS-CoV-2蛋白质组序列已存入GISAID。在此,我们利用这些序列评估了整个病毒蛋白质组中非同义突变体的发生率。我们的分析表明,SARS-CoV-2蛋白质的突变率差异很大,大多数病毒蛋白质的突变变异性很小。正如预期的那样,我们的计算捕捉到了疫情最初几个月出现的先前报道的突变,如D614G(刺突蛋白)、P323L(非结构蛋白12)和R203K/G204R(核衣壳蛋白),但也识别出了更多近期的突变,如A222V和L18F(刺突蛋白)以及A220V(核衣壳蛋白)等。我们全面的时间和地理分析显示出两个具有不同蛋白质组突变率的不同时期:2019年12月至2020年7月以及2020年8月至12月。值得注意的是,一些突变率因地理位置而异,主要是在2020年下半年的欧洲。此外,我们基于结构的分子分析在现有SARS-CoV-2蛋白质三维结构的背景下,对SARS-CoV-2的突变率进行了详尽评估。随着病毒在全球持续传播,这种新出现的从序列到结构的见解开始揭示SARS-CoV-2蛋白质的位点特异性突变耐受性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9060/7911924/996da2e2eaae/biology-10-00091-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验